Hematopoietic stem cell transplantation for primary immunodeficiencies

Hematology/Oncology Clinics of North America

Volumn 28, Issue 6, 2014, Pages 1157-1170

  Kang, Elizabeth ^a   Gennery, Andrew ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

Author keywords

Immune reconstitution; Immunodeficiency; Immunosuppression; Infection; Inflammation

Indexed keywords

CD40 LIGAND; DEDICATOR OF CYTOKINESIS 8; PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

CHROMOSOME MUTATION; CHRONIC GRANULOMATOUS DISEASE; COMBINED IMMUNODEFICIENCY; DNA REPAIR; ENGRAFTMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNE DEFICIENCY; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; WISKOTT ALDRICH SYNDROME; ALLOTRANSPLANTATION; BLOOD DONOR; HISTOCOMPATIBILITY TEST; IMMUNOLOGIC DEFICIENCY SYNDROMES; PROCEDURES; SURVIVAL; TREATMENT OUTCOME;

BLOOD DONORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84912068663     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.08.006     Document Type: Review

References (95)

1. Gatti R.A., Meuwissen H.J., Allen H.D., et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968, 2:1366-1369.
2. Bach F.H., Albertini R.J., Joo P., et al. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968, 2:1364-1366.
3. Griffith L.M., Cowan M.J., Kohn D.B., et al. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. JAllergy Clin Immunol 2008, 122:1087-1096.
4. Al-Herz W., Bousfiha A., Casanova J.L., et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2014, 5:162.
5. Buckley R.H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004, 22:625-655.
6. Rao K., Amrolia P.J., Jones A., et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005, 105:879-885.
7. Muller S.M., Ege M., Pottharst A., et al. Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients. Blood 2001, 98:1847-1851.
8. Palmer K., Green T.D., Roberts J.L., et al. Unusual clinical and immunologic manifestations of transplacentally acquired maternal T cells in severe combined immunodeficiency. JAllergy Clin Immunol 2007, 120:423-428.
9. Friedman N.J., Shiff S.E., Ward F.E., et al. Graft versus graft and graft versus host reactions after HLA-identical bone marrow transplantation in a patient with severe combined immunodeficiency with transplacentally acquired lymphoid chimerism. Pediatr Allergy Immunol 1991, 2:111-116.
10. Barrett M.J., Buckley R.H., Schiff S.E., et al. Accelerated development of immunity following transplantation of maternal marrow stem cells into infants with severe combined immunodeficiency and transplacentally acquired lymphoid chimerism. Clin Exp Immunol 1988, 72:118-123.
11. Gennery A.R., Slatter M.A., Grandin L., et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better?. JAllergy Clin Immunol 2010, 126:602-610.e1-11.
12. Buckley R.H., Schiff S.E., Schiff R.I., et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. NEngl J Med 1999, 340:508-516.
13. Fischer A., Griscelli C., Friedrich W., et al. Bone-marrow transplantation for immunodeficiencies and osteopetrosis: European survey, 1968-1985. Lancet 1986, 2:1080-1084.
14. Myers L.A., Patel D.D., Puck J.M., et al. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 2002, 99:872-878.
15. Brown L., Xu-Bayford J., Allwood Z., et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood 2011, 117:3243-3246.
16. Pai S.Y., Logan B.R., Griffith L.M., et al. Transplantation of 240 patients with severe combined immunodeficiency (SCID) from 2000-2009: a Primary Immune Deficiency Treatment Consortium report. N Engl J Med 2014, 371:434-446.
17. Chan K., Puck J.M. Development of population-based newborn screening for severe combined immunodeficiency. JAllergy Clin Immunol 2005, 115:391-398.
18. Puck J.M., SCID Newborn Screening Working Group Group population-based newborn screening for severe combined immunodeficiency: steps toward implementation. JAllergy Clin Immunol 2007, 120:760-768.
19. Buckley R.H. The long quest for neonatal screening for severe combined immunodeficiency. JAllergy Clin Immunol 2012, 129:597-604. [quiz: 605-6].
20. Flake A.W., Zanjani E.D. Treatment of severe combined immunodeficiency. NEngl J Med 1999, 341:291-292.
21. Flake A.W., Roncarolo M.G., Puck J.M., et al. Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. NEngl J Med 1996, 335:1806-1810.
22. Wengler G.S., Lanfranchi A., Frusca T., et al. In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI). Lancet 1996, 348:1484-1487.
23. Grunebaum E., Mazzolari E., Porta F., et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006, 295:508-518.
24. Fernandes J.F., Rocha V., Labopin M., et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood?. Blood 2012, 119:2949-2955.
25. Dvorak C, Hassan A, Slatter M, etal. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol, in press.
26. Hassan A., Lee P., Maggina P., et al. Absence of host natural killer cells is associated with engraftment permissiveness following non-conditioned allogeneic haematopoietic stem cell transplant for sever combined immunodeficiency. JAllergy Clin Immunol 2014, 133:1660-1666.
27. Dror Y., Gallagher R., Wara D.W., et al. Immune reconstitution in severe combined immunodeficiency disease after lectin-treated, T-cell-depleted haplocompatible bone marrow transplantation. Blood 1993, 81:2021-2030.
28. Bertrand G., Duprat E., Lefranc M.P., et al. Characterization of human FCGR3B*02 (HNA-1b, NA2) cDNAs and IMGT standardized description of FCGR3B alleles. Tissue Antigens 2004, 64:119-131.
29. Prockop S.E., Petrie H.T. Regulation of thymus size by competition for stromal niches among early T cell progenitors. JImmunol 2004, 173:1604-1611.
30. Slatter M.A., Brigham K., Dickinson A.M., et al. Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency. JAllergy Clin Immunol 2008, 121:361-367.
31. Borghans J.A., Bredius R.G., Hazenberg M.D., et al. Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency. Blood 2006, 108:763-769.
32. Cavazzana-Calvo M., Carlier F., Le Deist F., et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 2007, 109:4575-4581.
33. Dvorak C.C., Gilman A.L., Horn B., et al. Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34(+) cells and a fixed CD3(+) dose. Bone Marrow Transplant 2013, 48:508-513.
34. Friedrich W., Honig M., Muller S.M. Long-term follow-up in patients with severe combined immunodeficiency treated by bone marrow transplantation. Immunol Res 2007, 38:165-173.
35. Haddad E., Landais P., Friedrich W., et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998, 91:3646-3653.
36. Mazzolari E., Forino C., Guerci S., et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. JAllergy Clin Immunol 2007, 120:892-899.
37. Teigland C.L., Parrott R.E., Buckley R.H. Long-term outcome of non-ablative booster BMT in patients with SCID. Bone Marrow Transplant 2013, 48:1050-1055.
38. Recher M., Berglund L.J., Avery D.T., et al. IL-21 is the primary common gamma chain-binding cytokine required for human B-cell differentiation invivo. Blood 2011, 118:6824-6835.
39. Buckley R.H., Win C.M., Moser B.K., et al. Post-transplantation B cell function in different molecular types of SCID. JClin Immunol 2013, 33:96-110.
40. Booth C., Algar V.E., Xu-Bayford J., et al. Non-infectious lung disease in patients with adenosine deaminase deficient severe combined immunodeficiency. JClin Immunol 2012, 32:449-453.
41. Grunebaum E., Cutz E., Roifman C.M. Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency. JAllergy Clin Immunol 2012, 129:1588-1593.
42. Hassan A., Booth C., Brightwell A., et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase deficient severe combined immunodeficiency. Blood 2012, 120:3615-3624.
43. Schuetz C., Neven B., Dvorak C.C., et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood 2014, 123:281-289.
44. O'Marcaigh A.S., DeSantes K., Hu D., et al. Bone marrow transplantation for T-B- severe combined immunodeficiency disease in Athabascan-speaking native Americans. Bone Marrow Transplant 2001, 27:703-709.
45. Grunebaum E., Daneman A., Murguia-Favela L., et al. Multiple osteochondromas following irradiation-containing conditioning in severe combined immunodeficiency. Br J Haematol 2013, 161:446-448.
46. Straathof K.C., Rao K., Eyrich M., et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 2009, 374:912-920.
47. Schulz A.S., Glatting G., Hoenig M., et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood 2011, 117:4642-4650.
48. Brodsky R.A., Luznik L., Bolanos-Meade J., et al. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant 2008, 42:523-527.
49. Bertaina A., Merli P., Rutella S., et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B-cells in children with non-malignant disorders. Blood 2014, 124:822-826.
50. Kobayashi R., Ariga T., Nonoyama S., et al. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol 2006, 135:362-366.
51. Pai S.Y., DeMartiis D., Forino C., et al. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant 2006, 38:671-679.
52. Friedrich W., Schutz C., Schulz A., et al. Results and long-term outcome in 39 patients with Wiskott-Aldrich syndrome transplanted from HLA-matched and -mismatched donors. Immunol Res 2009, 44:18-24.
53. Moratto D., Giliani S., Bonfim C., et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011, 118:1675-1684.
54. Filipovich A.H., Stone J.V., Tomany S.C., et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 2001, 97:1598-1603.
55. Ochs H.D., Filipovich A.H., Veys P., et al. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant 2009, 15:84-90.
56. Gennery A.R., Khawaja K., Veys P., et al. Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. Blood 2004, 103:1152-1157.
57. Kikuta A., Ito M., Mochizuki K., et al. Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction. Bone Marrow Transplant 2006, 38:665-669.
58. McLauchlin J., Amar C.F., Pedraza-Diaz S., et al. Polymerase chain reaction-based diagnosis of infection with Cryptosporidium in children with primary immunodeficiencies. Pediatr Infect Dis J 2003, 22:329-335.
59. Hadzic N., Pagliuca A., Rela M., et al. Correction of the hyper-IgM syndrome after liver and bone marrow transplantation. NEngl J Med 2000, 342:320-324.
60. Jasinska A., Kalwak K., Trelinska J., et al. Successful haploidentical PBSCT with subsequent T-cell addbacks in a boy with HyperIgM syndrome presenting as severe congenital neutropenia. Pediatr Transplant 2013, 17:E37-40.
61. Kang E.M., Marciano B.E., DeRavin S., et al. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. JAllergy Clin Immunol 2011, 127:1319-1326. [quiz: 1327-8].
62. Seger R.A., Gungor T., Belohradsky B.H., et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 2002, 100:4344-4350.
63. Horwitz M.E., Barrett A.J., Brown M.R., et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. NEngl J Med 2001, 344:881-888.
64. Gungor T., Teira P., Slatter M., et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2014, 383:436-448.
65. Nakano T., Boku E., Yoshioka A., et al. Acase of McLeod phenotype chronic granulomatous disease who received unrelated cord blood transplantation. JPediatr Hematol Oncol 1999, 12:264.
66. Cole T., McKendrick F., Titman P., et al. Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. JClin Immunol 2013, 33:8-13.
67. Kuhns D.B., Alvord W.G., Heller T., et al. Residual NADPH oxidase and survival in chronic granulomatous disease. NEngl J Med 2010, 363:2600-2610.
68. Bonfim C.M., de Medeiros C.R., Bitencourt M.A., et al. HLA-matched related donor hematopoietic cell transplantation in 43 patients with Fanconi anemia conditioned with 60 mg/kg of cyclophosphamide. Biol Blood Marrow Transplant 2007, 13:1455-1460.
69. Pasquini R., Carreras J., Pasquini M.C., et al. HLA-matched sibling hematopoietic stem cell transplantation for Fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens. Biol Blood Marrow Transplant 2008, 14:1141-1147.
70. Albert M.H., Gennery A.R., Greil J., et al. Successful SCT for Nijmegen breakage syndrome. Bone Marrow Transplant 2010, 45:622-626.
71. Gruhn B., Seidel J., Zintl F., et al. Successful bone marrow transplantation in a patient with DNA ligase IV deficiency and bone marrow failure. Orphanet J Rare Dis 2007, 2:5.
72. Buck D., Moshous D., de Chasseval R., et al. Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV. Eur J Immunol 2006, 36:224-235.
73. Cagdas D., Ozgur T.T., Asal G.T., et al. Two SCID cases with cernunnos-XLF deficiency successfully treated by hematopoietic stem cell transplantation. Pediatr Transplant 2012, 16:E167-171.
74. Faraci M., Lanino E., Micalizzi C., et al. Unrelated hematopoietic stem cell transplantation for Cernunnos-XLF deficiency. Pediatr Transplant 2009, 13:785-789.
75. Gadalla S.M., Sales-Bonfim C., Carreras J., et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant 2013, 19:1238-1243.
76. Ayas M., Nassar A., Hamidieh A.A., et al. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure. Bone Marrow Transplant 2013, 48:1168-1172.
77. Henter J.I., Horne A., Arico M., et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48:124-131.
78. Stephan J.L., Donadieu J., Ledeist F., et al. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A. Blood 1993, 82:2319-2323.
79. Ouachee-Chardin M., Elie C., de Saint Basile G., et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics 2006, 117:e743-750.
80. Marsh R.A., Vaughn G., Kim M.O., et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 2010, 116:5824-5831.
81. Booth C., Gilmour K.C., Veys P., et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 2011, 117:53-62.
82. Marsh R.A., Rao K., Satwani P., et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood 2013, 121:877-883.
83. Pachlopnik Schmid J., Moshous D., Boddaert N., et al. Hematopoietic stem cell transplantation in Griscelli syndrome type 2: a single-center report on 10 patients. Blood 2009, 114:211-218.
84. Tardieu M., Lacroix C., Neven B., et al. Progressive neurologic dysfunctions 20 years after allogeneic bone marrow transplantation for Chediak-Higashi syndrome. Blood 2005, 106:40-42.
85. Barzaghi F., Passerini L., Bacchetta R. Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol 2012, 3:211.
86. Rao A., Kamani N., Filipovich A., et al. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 2007, 109:383-385.
87. Nademi Z., Slatter M., Gambineri E., et al. Single centre experience of haematopoietic SCT for patients with immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Bone Marrow Transplant 2014, 49:310-312.
88. Zhang Q., Davis J.C., Lamborn I.T., et al. Combined immunodeficiency associated with DOCK8 mutations. NEngl J Med 2009, 361:2046-2055.
89. McDonald D.R., Massaad M.J., Johnston A., et al. Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency. JAllergy Clin Immunol 2010, 126:1304-1305.e3.
90. Bittner T.C., Pannicke U., Renner E.D., et al. Successful long-term correction of autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency by hematopoietic stem cell transplantation. Klin Padiatr 2010, 222:351-355.
91. Ghosh S., Schuster F.R., Adams O., et al. Haploidentical stem cell transplantation in DOCK8 deficiency - successful control of pre-existing severe viremia with a TCRass/CD19-depleted graft and antiviral treatment. Clin Immunol 2014, 152:111-114.
92. Al-Mousa H., Hawwari A., Alsum Z. In DOCK8 deficiency donor cell engraftment post-genoidentical hematopoietic stem cell transplantation is possible without conditioning. JAllergy Clin Immunol 2013, 131:1244-1245.
93. Boztug H., Karitnig-Weiss C., Ausserer B., et al. Clinical and immunological correction of DOCK8 deficiency by allogeneic hematopoietic stem cell transplantation following a reduced toxicity conditioning regimen. Pediatr Hematol Oncol 2012, 29:585-594.
94. Barlogis V., Galambrun C., Chambost H., et al. Successful allogeneic hematopoietic stem cell transplantation for DOCK8 deficiency. JAllergy Clin Immunol 2011, 128:420-422.e2.
95. Metin A., Tavil B., Azik F., et al. Successful bone marrow transplantation for DOCK8 deficient hyper IgE syndrome. Pediatr Transplant 2012, 16:398-399.